Checkpoint Launches New Web Site.

Health/Medical Writers

LOS ANGELES--(BW HealthWire)--Feb. 26, 2001

Checkpoint (Pink Sheets OTC BB:CKPT) has launched its recently renovated Web site.

Retaining the domain name www.ckpt-genetics.com, the new Web site allows visitors to surf the site with more ease and to experience a more in-depth exploration of the possibilities and opportunities that the company offers to the public.

This is particularly significant at a time when manufacturers of pharmaceuticals such as Pravachol(R) publish information that, by necessity, includes warnings that their product "is not for everyone" (see their full-page ad in Wall Street Journal, Wednesday, Feb. 14, 2001, page A9). While the makers of Pravachol(R) must warn that "serious side effects can result" with their product, and urge that you "tell your doctor about any unexplained muscle pain or weakness you experience while on Pravachol," the informed reader should be stimulated by the advantages over such products of certain Checkpoint offerings under development.

Checkpoint's improvements are very important because some people are susceptible to the serious side effects that are associated with the existing cholesterol-lowering drugs that include the mentioned Pravachol(R) and also Mevacor(R), Lipitor(R), Lescol(R) and Baycol(R). Although severe reactions to the current generation of the cholesterol drugs are apparently relatively rare, the LA Times has reported on "hundreds of readers who experience intolerable side effects such as depression, memory problems, insomnia or muscle pain" and other adverse effects on quality of life (see LA Times, Monday, Feb. 12, 2001, page S2). Clearly, Checkpoint is working in one of the most worthwhile areas of consumer-oriented medical science and technology. The company has a uniquely innovative approach that goes beyond cholesterol and cholesterol lowering.

Checkpoint (full name: Checkpoint Genetics Pharmaceuticals Inc.) is a holding company that has a majority control over Checkpoint Genetics Inc. (www.cpgen.com), a development-stage company engaged in the production and distribution of nutritional and pharmaceutical products. The company's efforts are focused on harnessing research and application of pharmaceutical and nutritional products that are based on the active ingredients of the traditional Japanese diet. Through startup funding by Checkpoint, the operating company Checkpoint Genetics Inc. is in the process of enhancing product development, clinical research, manufacturing and marketing of the proprietary nutritional and pharmaceutical products. Visit the subsidiary operating company, Checkpoint Genetics Inc., at http://www.cpgen.com to learn about why cholesterol lowering is simply not enough. Find out about "Beyond Cholesterol."

Keeping up with the current multimedia technological trends and in preparation for forthcoming product marketing, Checkpoint has decided to review and change the appearance of its Web site. The company is optimistic that it is able to keep up with, and capitalize on, the growing demands of the increasingly health-conscious public and the effect of these demands on the entire pharmaceutical industry.

Certain statements in this news release constitute "forward-looking statements" that are subject to risks and uncertainties that may cause the actual results of the company to be different from expectations, express or implied by such forward-looking statements. Such factors include, but are not limited to, uncertainty of market acceptance of the company's products; the uncertainty of expenses associated with the operations, which may affect the profitability of the company; uncertainty of regulatory approvals; the uncertainty of market conditions; and other risk factors detailed in the company's Securities and Exchange Commission filings.